Search Result

Pathways Recommended:	NF-κB

Results for "

NF-Κb

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NF-κB (411) 5-HT Receptor (1) Acyltransferase (12) ADC Cytotoxin (1) Adenosine Receptor (4) Adrenergic Receptor (2) AIM2 (1) Akt (26) AMPK (5) Amylases (1) Amyloid-β (11) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (4) Antibiotic (11) AP-1 (6) Apoptosis (132) Arginase (1) Aryl Hydrocarbon Receptor (1) Autophagy (42) Bacterial (33) Bcl-2 Family (7) Biochemical Assay Reagents (2) Btk (1) c-Myc (2) Calcium Channel (9) Carbonic Anhydrase (1) Caspase (9) CCR (2) CDK (3) Chloride Channel (1) Cholinesterase (ChE) (2) COX (62) CXCR (3) Cytochrome P450 (2) Dengue virus (1) Deubiquitinase (2) DNA/RNA Synthesis (4) Dopamine Receptor (1) E1/E2/E3 Enzyme (7) EGFR (2) Elastase (1) Endogenous Metabolite (57) Epigenetic Reader Domain (4) ERK (30) Estrogen Receptor/ERR (3) Eukaryotic Initiation Factor (eIF) (1) Factor Xa (1) FAK (1) Ferroptosis (10) FGFR (1) Flavivirus (1) Fungal (10) Glucocorticoid Receptor (4) GLUT (4) Glutathione S-transferase (3) HDAC (7) HIF/HIF Prolyl-Hydroxylase (4) Histone Acetyltransferase (2) Histone Demethylase (1) HIV (13) HMG-CoA Reductase (HMGCR) (1) HSP (1) HSV (4) IAP (2) IGF-1R (1) IKK (23) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (8) Insulin Receptor (1) Integrin (1) Interleukin Related (31) IRAK (2) Isotope-Labeled Compounds (14) JAK (6) JNK (16) Keap1-Nrf2 (21) Leukotriene Receptor (1) Lipoxygenase (1) MALT1 (2) MAP3K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (3) MEK (10) Melanocortin Receptor (1) mGluR (3) Microtubule/Tubulin (2) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (5) Mitophagy (13) MMP (12) Monoamine Oxidase (1) mTOR (5) MyD88 (2) Na+/H+ Exchanger (NHE) (1) Na+/K+ ATPase (3) nAChR (3) Necroptosis (1) NO Synthase (25) NOD-like Receptor (NLR) (7) Nuclear Factor of activated T Cells (NFAT) (2) Opioid Receptor (2) Organoid (1) Oxidative Phosphorylation (2) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (37) PAK (6) Parasite (15) PARP (5) PD-1/PD-L1 (2) PGE synthase (2) Phosphatase (3) Phosphodiesterase (PDE) (6) PI3K (5) PKA (1) PKC (3) Potassium Channel (3) PPAR (16) Progesterone Receptor (1) PROTACs (4) Protease Activated Receptor (PAR) (2) Proteasome (14) PTEN (1) Pyroptosis (1) Pyruvate Kinase (1) RANKL/RANK (1) Ras (1) Reactive Oxygen Species (23) Ribosomal S6 Kinase (RSK) (1) RIP kinase (3) SARS-CoV (4) Ser/Thr Protease (1) Sirtuin (6) Small Interfering RNA (siRNA) (6) Sodium Channel (13) SphK (1) STAT (13) STING (6) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (45) Toll-like Receptor (TLR) (21) Topoisomerase (2) TrxR (1) Tyrosinase (3) VEGFR (4) Virus Protease (5) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (296) Cardiovascular Disease (60) Endocrinology (10) Infection (78) Inflammation/Immunology (426) Metabolic Disease (40) Neurological Disease (58)
Click Chemistry:	Alkynes (1)

659

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

293

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

NF-κB-IN-1 2 Publications Verification	IKK	Cancer
NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent NF-κB signaling pathway inhibitor. NF-κB-IN-1 directly inhibits IKK to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells .

NF-κB-IN-11	NF-κB	Inflammation/Immunology
NF-κB-IN-11 (Compound 3i) is a *NF-κB* inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .

NF-κB-IN-13	NF-κB	Inflammation/Immunology
NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced *NF-κB* activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .

NF-κB-IN-9	NF-κB	Cancer
NF-κB-IN-9 is a nuclear factor kappa B (NF-κB) targeting sonosensitizer (λex/λem=489/628 nm). NF-κB-IN-9 exhibits strong inhibition on NF-κB signaling due to its two resveratrol units in one molecule. NF-κB-IN-9 has anti-tumor activity and shows remarkable sonocytotoxicity against cancer cells. NF-κB-IN-9 has biosafety in eenograft mice model.

NF-κB-IN-3	NF-κB	Cancer
NF-κB-IN-3 (Compound 2) is a *NF-κB* inhibitor with an IC₅₀ of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .

NF-κB-IN-4	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated *NF-κB* pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .

NF-κB-IN-2	NF-κB	Neurological Disease
NF-κB-IN-2 inhibits TNF-α-induced canonical NF-κB signaling in PC-3 cells.

NF-κB-IN-10	NF-κB	Cardiovascular Disease
NF-κB-IN-10 (compound E1) is an *NF-κB* inhibitor that can improve heart failure by reducing oxidative stress and inflammation by regulating *Nrf2/NF-κB* signaling pathway. NF-κB-IN-10 inhibits LPS-induced NO production and expression of iNOS and COX-2 in RAW264.7 cells. NF-κB-IN-10 can be used in the research of cardiovascular diseases .

NF-κB-IN-12	NF-κB	Inflammation/Immunology
NF-κB-IN-12 (compound 3h) is a potent *NF-κB* inhibitor, with an IC₅₀ of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research .

NF-κB-IN-5	NF-κB Apoptosis	Cancer
NF-κB-IN-5 (compound 4d) is an orally active and potent *NF-κB* inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC₅₀ values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .

NF-κB-IN-14	NF-κB Toll-like Receptor (TLR)	Inflammation/Immunology
NF-κB-IN-14 (compound 5e) significantly inhibits nitric oxide production in LPS-induced macrophages (IC₅₀: 6.4 μM). NF-κB-IN-14 disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the *NF-κB* signaling pathway suppression. NF-κB-IN-14 reduces ear edema and inflammation in an atopic dermatitis mouse model .

NF-κB-IN-6	NF-κB	Inflammation/Immunology
NF-κB-IN-6 (Compound 3d) is an anti-inflammatory agent through the mechanism of decreasing the protein expressions of iNOS and COX-2 by suppressing *NF-κB* signaling pathway. NF-κB-IN-6 inhibits NO production in LPS-induced RAW264.7 cells with an IC₅₀ of 23.1 μM .

NF-κB-IN-15	NF-κB	Inflammation/Immunology
NF-κB-IN-15 (compound 14r) is a potent *NF-κB* inhibitor. NF-κB-IN-15 decreases the NO levels and inhibits the release of IL-6, TNF-α, and IL-1β in LPS (HY-D1056) -induced cells. NF-κB-IN-15 inhibits LPS-induced phosphorylation of p65 and degradation of IκBα. NF-κB-IN-15 shows anti-inflammatory activity has the potential for the research of acute lung injury (ALI) .

NF-κB/MAPK-IN-1	NF-κB p38 MAPK NO Synthase COX	Inflammation/Immunology
NF-κB/MAPK-IN-1 (compound 11a) is a potent inhibitor of *NF-κB* and MAPK pathway. NF-κB/MAPK-IN-1 shows inhibitory activity against NO production, with an IC₅₀ of 6.96 µM. NF-κB/MAPK-IN-1 suppresses LPS-induced iNOS, COX-2, ERΚ and P38 signaling activation. NF-κB/MAPK-IN-1 can prevent LPS induced inflammatory response in macrophages. NF-κB/MAPK-IN-1 can be used for rheumatoid arthritis (RA) research .

NF-κB-IN-8	NF-κB	Inflammation/Immunology
NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI) .

NF-κB/PON1-IN-1	NF-κB Reactive Oxygen Species	Cancer
NF-κB/PON1-IN-1 (Compound 16) is a *NF-κB/PON1* pathway inhibitor. NF-κB/PON1-IN-1 has antioxidant (IC₅₀ = 45.76 µM) and hepatoprotective activities .

*Akt/NF-κB/JNK-IN-1*	Akt NF-κB JNK TNF Receptor COX	Inflammation/Immunology
Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, *NF-κB* and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC₅₀ of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .

*AP-1/NF-κB* activation inhibitor 1** 1 Publications Verification	NF-κB	Inflammation/Immunology
AP-1/NF-κB activation inhibitor 1 is a potent AP-1 and *NF-κB* mediated transcriptional activation inhibitor (IC₅₀=1 μM), without blocking basal transcription driven by the β-actin promoter. AP-1/NF-κB activation inhibitor 1 has a similar inhibitory effect on the production of IL-2 and IL-8 levels in stimulated cells .

*Akt/NF-κB/MAPK-IN-1*	p38 MAPK ERK JNK Interleukin Related TNF Receptor NO Synthase COX	Others
Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC₅₀=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways .

*TLR4/NF-κB/MAPK-IN-1*	NF-κB p38 MAPK Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology
TLR4/NF-κB/MAPK-IN-1 is a new type of antineuroinflammatory agent by suppressing TLR4/NF-kB/MAPK pathways.

PTD-p65-P1 Peptide TFA 3 Publications Verification	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

PTD-p65-P1 Peptide	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

Quinoclamine 2 Publications Verification	NF-κB	Cancer
Quinoclamine, a naphthoquinone derivative, is a *NF-κB* inhibitor. Quinoclamine exhibits anti-cancer activity .

Avenanthramide-C methyl ester	NF-κB	Inflammation/Immunology
Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity .

Asperbisabolane L	NF-κB	Inflammation/Immunology
Asperbisabolane L, a sesquiterpenoid, exerts the anti-inflammatory activity by inhibiting the *NF-κB*-activated pathway. Asperbisabolane L inhibits the translocation of NF-κB from cytoplasm to the nucleus. Asperbisabolane L also inhibits NO production in LPS-activated BV-2 microglia cells .

ACAT-IN-7	Acyltransferase	Inflammation/Immunology
ACAT-IN-7 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-7 inhibits NF-κB mediated transcription .

ACAT-IN-3	Acyltransferase	Inflammation/Immunology
ACAT-IN-3 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-3 inhibits NF-κB mediated transcription .

Echinulin Echinuline	NF-κB	Inflammation/Immunology
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to *NF-κB* activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent .

ACAT-IN-4	Acyltransferase	Inflammation/Immunology
ACAT-IN-4 (Example 208) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-4 inhibits NF-κB mediated transcription .

ACAT-IN-5	Acyltransferase	Inflammation/Immunology
ACAT-IN-5 (example 19) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-5 inhibits NF-κB mediated transcription .

ACAT-IN-8	Acyltransferase	Inflammation/Immunology
ACAT-IN-8 (example 206) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-8 inhibits NF-κB mediated transcription .

ACAT-IN-4 hydrochloride	Acyltransferase	Inflammation/Immunology
ACAT-IN-4 hydrochloride (Example 208) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-4 hydrochloride inhibits NF-κB mediated transcription .

Aconine 2 Publications Verification Jesaconine	NF-κB	Inflammation/Immunology Cancer
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced *NF-κB* activation.

SRTCX1002	Sirtuin	Inflammation/Immunology
SRTCX1002 is a potent activator of SIRT1 (STAC), suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB Activity. SRTCX1002 suppresses stimuli-induced NF-κB transcriptional activation and LPS-induced TNFα secretion with IC₅₀s of 0.71 and 7.58 µM, respectively .

9-Hydroxycanthin-6-one	NF-κB	Inflammation/Immunology
9-Hydroxycanthin-6-one is an alkaloid compound. 9,10-Dimethoxycanthin-6-one exhibits *NF-κB* inhibitory effects with an IC₅₀ of 3.8 μM .

Teuclatriol	NF-κB	Inflammation/Immunology
Teuclatriol is an *NF-κB* inhibitor can be isolated from salvia mirzayanii, has anti-inflammatory effects. Teuclatriol inhibits TNF-α secretion in a dose-dependent manner .

9,10-Dimethoxycanthin-6-one	NF-κB	Inflammation/Immunology
9,10-Dimethoxycanthin-6-one is an alkaloid compound. 9,10-Dimethoxycanthin-6-one exhibits *NF-κB* inhibitory effects with an IC₅₀ of 19.5 μM .

Anti-inflammatory agent 48	NF-κB	Inflammation/Immunology
Anti-inflammatory agent 48 is an anti-inflammatory agent based on its role in inhibiting the *NF-κB* signaling pathway and activating HO-1 expression .

Sappanone A	NF-κB Keap1-Nrf2	Inflammation/Immunology
Sappanone A is a homoisoflavanone which exhibits anti-inflammatory effects via modulation of Nrf2 and *NF-κB*. Sappanone can attenuate allergic airway inflammation in Ovalbumin-induced asthma .

Helenalin acetate 1 Publications Verification	Histone Demethylase NF-κB	Inflammation/Immunology Cancer
Helenalin acetate, a natural *NF-κB* inhibitor, is a potent C/EBPβ inhibitor. Helenalin acetate has anti-inflammatory and anticancer activities .

Narasin	Bacterial Apoptosis Parasite NF-κB Antibiotic	Infection Cancer
Narasin is a cationic ionophore and coccidiostat agent. Narasin inhibits *NF-κB* signaling and induces tumor cells apoptosis. Narasin has antimicrobial and anticancer activity .

ACAT-IN-2	Acyltransferase	Inflammation/Immunology
ACAT-IN-2 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 187. ACAT-IN-2 inhibits NF-κB mediated transcription .

ACAT-IN-9	Acyltransferase	Inflammation/Immunology
ACAT-IN-9 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription .

(−)-N-Hydroxyapiosporamide NHAP	NF-κB	Cancer
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an *NF-κB* inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .

Goshonoside F5	NF-κB	Inflammation/Immunology
Goshonoside F5 can be isolated from the unripe fruits of Rubus chingii. Goshonoside F5 has anti-inflammatory activity, and inhibits NF-κB and MAPK signaling pathway .

ACAT-IN-10	Acyltransferase	Inflammation/Immunology
ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription .

Cat. No.	Product Name

HY-L014

NF-κB Signaling Compound Library

798 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 798 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

HY-L172

Immunopotentiator Compound Library

77 Compounds compounds

Immunity refers to the ability of the body to resist the invasion of pathogenic microorganisms and resist a variety of diseases. Immunocompromised will inevitably lead to a series of diseases. Immunopotentiator are a class of compounds that enhance immune function and induce immune response. Immunopotentiator can activate the proliferation and differentiation of one or more kinds of immune active cells in the body, promote the secretion of lymphocytes, and then enhance the immune function of the body. Immunopotentiator are mainly used in the treatment of tumors, infectious diseases and immunodeficiency diseases. In addition, immunopotentiator are often used as adjuvants in combination with vaccine antigens to enhance the immunogenicity of vaccines.

MCE designs a unique collection of 77 compounds with definite or potential Immunopotentiating effect, mainly targeting the NOD-like Receptor (NLR), Toll-like Receptor (TLR), NF-κB, etc. It is an effective tool for development and research of anti-cancer, anti-infectious diseases and anti-immunodeficiency diseases compounds.

HY-L037

Antioxidant Compound Library

1478 compounds

Oxidative stress is an imbalance of free radicals and antioxidants in the body, which can lead to cell and tissue damage. Oxidative stress can be responsible for the induction of several diseases, both chronic and degenerative, as well as speeding up body aging process and cause acute pathologies. Antioxidants are a class of compounds able to counteract oxidative stress and mitigate its effects on individuals’ health, gained enormous attention from the biomedical research community. Antioxidants have long been substantial and amenable therapeutic arsenals for multifarious diseases such as AD and cancer.

MCE Antioxidant Compound Library contains 1478 compounds that act as antioxidants for high throughput screening (HTS) and high content screening (HCS). This library is a useful tool for discovery new antioxidants and oxidative stress research.

HY-L090

Transcription Factor-Targeted Library

1278 compounds

Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.

MCE offers a unique collection of 1278 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.

HY-L124

Anti-Prostate Cancer Compound Library

2278 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 2278 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L103

Anti-Colorectal Cancer Compound Library

1607 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1607 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L074

Anti-Breast Cancer Compound Library

1925 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1925 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-149696

IR-Crizotinib

Dyes

IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC₅₀=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Fluorescent Dye

Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

Cat. No.	Product Name	Type

HY-125864

Fibrinogen (Bovine)

Native Proteins

Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-P1956

Human serum albumin

1 Publications Verification

HSA

Native Proteins

Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO ⁻) in the vascular wall, contributing to the reduction of blood pressure .

HY-W042416

N,N-Dimethylacetamide DMAc	Co-solvents
N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the *NF-κB* signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease .

HY-W016412

Coenzyme Q0

2 Publications Verification

CoQ0

Biochemical Assay Reagents

Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling .

HY-B0185G

Lidocaine (GMP)

Lignocaine (GMP)

Biochemical Assay Reagents

HY-141582

Ceramide 3

N-Stearoyl phytosphingosine

Biochemical Assay Reagents

C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation.

Cat. No.	Product Name	Target	Research Area

HY-P1832A

PTD-p65-P1 Peptide TFA 3 Publications Verification	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

HY-P0151

SN50

Maximum Cited Publications

33 Publications Verification

NF-κB Inflammation/Immunology

SN50 is a cell permeable inhibitor of NF-κB translocation.

HY-P1860

TNF-α (31-45), human 5 Publications Verification	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology Cancer
TNF-α (31-45), human is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-P1832

PTD-p65-P1 Peptide	NF-κB Apoptosis	Inflammation/Immunology Cancer
PTD-p65-P1 Peptide is a potent, selective nuclear transcription factor *NF-κB* inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis .

HY-P1860A

TNF-α (31-45), human TFA	TNF Receptor NF-κB Apoptosis	Inflammation/Immunology
TNF-α (31-45), human TFA is a potent *NF-kB* pathway activator. TNF-αis a proinflammatory cytokine that induces necrosis or apoptosis. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis .

HY-P3031

Mitogen-activated protein kinase 1 MAPK1	p38 MAPK NF-κB	Inflammation/Immunology
Mitogen-activated protein kinase 1 (MAPK1) can activate the downstream *p38/NF-κB* pathway. Mitogen-activated protein kinase 1 can regulate cellular processes in various sepsis-associated diseases. MAPK-catalyzed phosphorylation of substrate proteins functions as a switch to turn on or off the activity of the substrate protein .

HY-P1847

IKKγ NBD Inhibitory Peptide	NF-κB	Cancer
IKKγ NBD Inhibitory Peptide is a highly specific inhibitor *NF-κB* inhibitor. IKKγ NBD Inhibitory Peptide acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .

HY-P1847A

IKKγ NBD Inhibitory Peptide TFA	NF-κB	Inflammation/Immunology
IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor *NF-κB* inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .

HY-138096

Z-LLF-CHO Z-Leu-Leu-Phe-CHO	Proteasome	Cancer
Z-LLF-CHO (Z-Leu-Leu-Phe-CHO) is a potent inhibitor of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex (K_i = 460 nM). Z-LLF-CHO is also a NF-κB nuclear translocation inhibitor .

HY-P1259

PR-39	Proteasome Bacterial	Inflammation/Immunology
PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 reversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P1259A

PR-39 TFA	Proteasome Bacterial	Inflammation/Immunology
PR-39 TFA, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor. PR-39 TFAreversibly binds to the α7 subunit of the proteasome and blocks degradation of NF-κB inhibitor IκBα by the ubiquitin-proteasome pathway. PR-39 TFA stimulates angiogenesis, inhibits inflammatory responses and significant reduces myocardial infarct size in mice .

HY-P1098

Ac2-26 3 Publications Verification	NF-κB	Inflammation/Immunology
Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue .

HY-P1098A

Ac2-26 TFA 3 Publications Verification	NF-κB	Inflammation/Immunology
Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue .

HY-100538A

DTP3 TFA 1 Publications Verification	DNA/RNA Synthesis JNK	Cancer
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 also activates iNOS expression and NO production in mouse macrophages .

HY-P1181A

Pam2CSK4 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4 (TFA), a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 (TFA) promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages .

HY-P1409

ADWX 1	Potassium Channel	Inflammation/Immunology
ADWX 1 is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC₅₀ value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 can be used to study T cell-mediated autoimmune diseases .

HY-P10081

CTP-NBD

NF-κB Inflammation/Immunology

CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study

HY-P2036A

FSL-1 TFA 3 Publications Verification	Toll-like Receptor (TLR) MMP HSV Antibiotic	Infection
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection . FSL-1 TFA induces MMP-9 production through TLR2 and *NF-κB/AP-1* signaling pathways in monocytic THP-1 cells .

HY-P3229

SN52 1 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of *NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB* heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-P3151A

Gliadin p31-43 TFA	Peptides	Inflammation/Immunology
Gliadin p31-43 TFA is an undigested gliadin peptide. Gliadin p31-43 TFA induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 TFA can be used for celiac disease research .

HY-P3151

Gliadin p31-43	Peptides	Inflammation/Immunology
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research .

HY-P1258

PSI Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO	Proteasome	Infection Cancer
PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

HY-P1258A

PSI TFA Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA	Proteasome	Infection Cancer
PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .

Cat. No.	Product Name	Target	Research Area

HY-P9930

Evolocumab 1 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

Cat. No.	Product Name	Chemical Structure

HY-78131BS

(R)-(-)-Ibuprofen-d3
(R)-(-)-Ibuprofen-d₃ is the deuterium labeled (R)-(-)-Ibuprofen. (R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, inactive on COX, inhibits NF-κB activation; (R)-(-)-Ibuprofen exhibits anti-inflammatory and antinociceptive effects.

HY-B0167S

Salicylic acid-d6
Salicylic acid-d₆ is a deuterium labeled Salicylic acid. Salicylic acid inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation[1].

HY-N1380S1

Guaiacol-d3
Guaiacol-d₃ is the deuterium labeled Guaiacol. Guaiacol, a phenolic compound, inhibits LPS-stimulated COX-2 expression and NF-κB activation. Guaiacol has an anti-inflammatory activity[1].

HY-N1380S

Guaiacol-d7
Guaiacol-d₇ is the deuterium labeled Guaiacol[1]. Guaiacol, a phenolic compound, inhibits LPS-stimulated COX-2 expression and NF-κB activation[1]. Anti-inflammatory activity[2].

HY-N1380S3

Guaiacol-d4
Guaiacol-d₄ is the deuterium labeled Guaiacol[1]. Guaiacol, a phenolic compound, inhibits LPS-stimulated COX-2 expression and NF-κB activation[1]. Anti-inflammatory activity[2].

HY-N1380S2

Guaiacol-13C6
Guaiacol- ¹³C₆ is the ¹³C labeled Guaiacol[1]. Guaiacol, a phenolic compound, inhibits LPS-stimulated COX-2 expression and NF-κB activation[1]. Anti-inflammatory activity[2].

HY-N1380S4

Guaiacol-d4-1
Guaiacol-d₄-1 is the deuterium labeled Guaiacol[1]. Guaiacol, a phenolic compound, inhibits LPS-stimulated COX-2 expression and NF-κB activation[1]. Anti-inflammatory activity[2].

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-B0289S

Erdosteine-13C4
Erdosteine- ¹³C₄ is a ¹³C-labeled Erdosteine. Erdosteine inhibits lipopolysaccharide (LPS)-induced NF-κB activation[1][2]. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects[3].

HY-32735S

Triptolide-d3
Triptolide-d₃ is the deuterium labeled Triptolide. Triptolide is a diterpenoid triepoxide extracted from the root of Tripterygium wilfordii with immunosuppressive, anti-inflammatory, antiproliferative and antitumour effects. Triptolide is a NF-κB activation inhibitor[1][2][3][4][5][6].

HY-14655S

Sulfasalazine-d4
Sulfasalazine-d₄ is the deuterium labeled Sulfasalazine. Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer[1][2][3][4].

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-N0005S

Curcumin-d6
Curcumin-d₆is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.

HY-15027S1

5-Aminosalicylic acid-d3
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].

HY-15027S2

5-Aminosalicylic acid-13C6
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].

HY-N0001S

(±)-Epicatechin-13C3
(±)-Epicatechin- ¹³C₃ is the ¹³C labeled (±)-Epicatechin. (-)-Epicatechin (HY-N0001) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB[1].

HY-137315S

TML-6-d3
TML-6-d₃ is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-

HY-B0808S1

Oxaprozin-d5
Oxaprozin-d₅ is deuterium labeled Oxaprozin. Oxaprozin is an inhibitor of both COX-1 and COX-2 with IC50s of 2.2 μM and 36 μM for human platelet COX-1 and IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB.

HY-10227S

Bortezomib-d8
Bortezomib-d₈ is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].

HY-B0185AS

Lidocaine-d10 hydrochloride

Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia[2].

HY-B0185S1

Lidocaine-d10

Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-B0185S

Lidocaine-d10 N-Oxide

N-Oxide Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].

HY-B0185AS1

Lidocaine-d6 hydrochloride

Lidocaine-d₆ (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].

HY-W018772S15

D-Ribose(mixture of isomers)-13C5

D-Ribose(mixture of isomers)- ¹³C₅ isomers)- ¹³C₅ is the ¹³C labeled D-Ribose(mixture of isomers)[1]. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner[1].

HY-W018772S16

D-Ribose-1,2-13C2

D-Ribose-1,2- ¹³C₂ is the ¹³C labled D-Ribose(mixture of isomers) (HY-W018772) . D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner .

HY-13010S

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-113439S

12-HETE-d8
12-HETE-d₈ is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway[1].12-HETE has both anti-thrombotic and pro-thrombotic effects[2]. 12-HETE is a neuromodulator[3].

HY-113509S

Lipoxin A4-d5

Lipoxin A4-d₅ is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].

HY-N0492S

α-Lipoic Acid-d5
α-Lipoic Acid-d₅ is the deuterium labeled α-Lipoic Acid. α-Lipoic Acid is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation[1][2][3]. α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells[4].

HY-13295S

Vinpocetine-d5

Vinpocetine-d₅ is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders[1][2][3].

HY-12383S

Pelubiprofen-13C,d3

Pelubiprofen- ¹³C,d₃ is the ¹³C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80245

NF-κB p65 Antibody	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
NF-κB p65 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 65 kDa, targeting to NF-κB p65. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

HY-P80244

NF-κB p105/p50 Antibody	WB, ICC, IHC-P	Human, Mouse
NF-κB p105/p50 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 50 kDa, targeting to NF-κB p105/p50. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P80470

*Phospho-NF-κB* p65 (Ser529) Antibody**	WB, IP, FC, IHC-P	Human
Phospho-NF-κB p65 (Ser529) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 60 kDa, targeting to Phospho-NF-κB p65(S529). It can be used for WB,IP,FC,IHC-P assays with tag free, in the background of Human.

HY-P81238

*Phospho-NF-κB* p65 (Ser536) Antibody** NF-kB p65 (phospho S536); p-NF-Κb p65(Phospho-Ser536); RELA(phospho S536); NF kB P65; NF-kB p65; NFKBp65; NF-Κbp65; p65 NF kappaB; p65 NFkB; NFKBp65; RELA; Transcription Factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A; p65NFKB; Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NFKB 3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells; TF65_HUMAN. NFΚb-p65; NFΚb p65; NF Κb-p65; NFΚbp65	WB; IHC; Flow-Cyt;	Human, Mouse, Rat, (predicted: Chicken, Dog, Cow, Horse, )

HY-P81239

*Phospho-NF-κB* p65 (Ser276) Antibody** NF-kB p65 (phospho S276); p-NF-kB p65 (phospho S276); RELA(phospho S276); NF kB P65; NF-kB p65; NF kB P65; NF-Κbp65; p65 NF kappaB; p65 NFkB; RELA; Transcription Factor p65; v rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)); V Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A; v rel reticuloendotheliosis viral oncogene homolog A (avian); v-rel reticuloendotheliosis viral oncogene homolog A; p65NFKB; Avian reticuloendotheliosis viral (v rel) oncogene homolog A; MGC131774; NFKB 3; NFKB3; Nuclear Factor NF Kappa B p65 Subunit; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells. NFΚb-p65; NFΚb p65; NF Κb-p65; NFΚbp65	ELISA; IHC-P; IHC-F; Flow-Cyt; ICC; IF;	Human, Mouse, Rat, (predicted: Dog, Pig, Cow, Horse, )

Cat. No.	Product Name		Classification

HY-108039

Bezisterim HE 3286; NE-3107		Alkynes
Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial *NF-κB* inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis . Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

NF-Κb

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products